Kyle J. Dunton
Uxbridge Business Park
Uxbridge, United Kingdom
Uxbridge, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Estimating the societal impact of medical interventions: a case study in metastatic breast cancer.
Journal: Journal of comparative effectiveness research
Published: May 22, 2026
Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 23, 2026
Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States.
Journal: Breast (Edinburgh, Scotland)
Published: October 16, 2025
Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison.
Journal: Frontiers in oncology
Published: September 18, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 11, 2025
Real-World Characteristics, Treatment Patterns, and Outcomes in Advanced HER2 (ERBB2)-Mutant Non-Small Cell Lung Cancer: A Retrospective Study of Single Centers in France and Germany.
Journal: Clinical therapeutics
Published: June 05, 2025
Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer.
Journal: MDM policy & practice
Published: January 31, 2025
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study.
Journal: Breast cancer research and treatment
Published: December 20, 2024
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
Journal: The oncologist
Published: September 16, 2024
Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy.
Journal: Advances in therapy
Published: August 14, 2024
Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 12, 2024
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018).
Journal: ESMO real world data and digital oncology
Published: June 03, 2024
Last Updated: 09/26/2026